Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only mCRPC
2024-511660-89-00Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radium-223 dichloride, docetaxel and prednisone in metastatic castration-resistant prostate cancer (mCRPC) and castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: HRQoL clinical benefit. Started Jul 2024; status: completed.
02
Drugs
radium-223 dichloridedocetaxelprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2024-511660-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511660-89-00.